Celltrion’s Remsima on course to become Korea’s 1st blockbuster drug

Celltrion Inc.'s Remsima, the world’s first biosimilar monoclonal antibody, is on track to exceed 1 trillion won ($713 million) in sales this ...

Celltrion eyes M&A in Europe, $3.3 bn Zymfentra sales: chairman

WASHINGTON, D.C. – South Korean biosimilar giant Celltrion Inc. is accelerating its push to transform into a novel drug developer, going after...

Celltrion, WuXi XDC to develop new antibody-drug conjugates

South Korea’s Celltrion Inc. has signed a business agreement with China’s WuXi XDC to jointly develop new antibody-drug conjugates (ADC)...

Orion to buy control of biotech startup LegoChem for $415 mn

South Korea’s snack and confectionery maker Orion Group has agreed to buy a controlling stake in LegoChem Biosciences Inc., a Korean biotech s...

Lotte builds US antibody-drug conjugate plant with $82 mn

South Korea’s Lotte Biologics Co. is establishing an antibody-drug conjugate (ADC) factory in Syracuse, New York, with an investment of 110 bi...

S.Korea's EuBiologics to receive support from Gates Foundation

South Korea's biopharmaceutical company EuBiologics Co. announced on Wednesday that its meningococcal pentavalent conjugate vaccine EuMCV5 under dev...

Bridge Biotherapeutics, Pinotbio develop lung cancer treatment

South Korea's biotech companies Bridge Biotherapeutics Inc. and Pinotbio on Thursday said they will jointly develop new antibody-drug conjugates (AD...

LegoChem’s biotech platform drives 28% share price spike over last month

The rise of the platform economy is a global phenomenon. The spread of the coronavirus pandemic has accelerated the use of contactless technology an...

Celltrion, Mirae to take largest stake in UK biotech firm

South Korean biosimilar maker Celltrion Inc. and Mirae Asset Group have agreed to an investment that will render them the top shareholder in Iksuda ...